Revision of the USP Chapter on Spectroscopic Methods

Recommendation
13-15 May 2025
Vienna, Austria
Practical Approaches for USP General Chapter <1058> Compliance in the QC Laboratory
In the USP Pharmacopeial Forum 40(1), a "Stimuli to the Revision Process" article states that the responsible working group of the USP has conducted a review of the existing general chapters on spectroscopic methods.
The goal of this review was to establish a uniform concept for all the spectroscopic methods and generate a common format. As a result, consistency in the overall approach and ease of use in the future should also be enabled for the user.
The general chapters smaller than <1.000> show how to correctly use the methods ("suitability for use"), whereas the general chapters greater than <1.000> additionally provide so-called "best practices". Those chapters also include provisions on instrument qualification and on validation of spectroscopic methods.
That's why some of these General USP Chapters have been once again published in this issue of the Pharmacopeial Forum:
<852> Atomic Absorption Spectroscopy
<853> Fluorescence Spectroscopy
<854> Mid-Infrared Spectroscopy
<857> Ultraviolet-Visible Spectroscopy
and as supplement to these chapters:
<1852> Atomic Absorption Spectroscopy - Theory and Practice
<1853> Fluorescence Spectroscopy - Theory and Practice
<1854> Mid-Infrared Spectroscopy - Theory and Practice
All these chapters are planned for the edition USP38/NF33 and will thus become effective in the coming year.
You will find more information on the USP Pharmacopeial Forum website.
PS: Dr Chris Burgess, member of this USP experts group, will present the new USP developments in spectroscopy during the ECA course "Analytical Instrument Qualification" from 19-21 May 2014 in Berlin, Germany.
Related GMP News
09.05.2025New ECA Guidance on Sampling and Sample Management
07.05.2025Public Consultation on ICH M13B Guideline on Bioequivalence launched in Switzerland
07.05.2025BioPhorum publishes Guidance for ICH Q2(R2) and Q14 Implementation
23.04.2025OTC Drug Production Ceased after FDA Warning Letter
23.04.2025EMA publishes Draft of ICH M13B Guideline on Bioequivalence
16.04.2025EMA publishes four new product-specific Bioequivalence Guidance